imILT® is developed for metastatic cancer, meaning cancer that has spread from the part in the body where it started (the primary site). When cancer cells break away from a tumor, they can travel to other areas of the body through the bloodstream or the lymph system (which contains a collection of vessels that carry fluid and immune system cells). With imILT® treatment activated cytotoxic T-cells home in on and kill tumor tissue throughout the body and set an immunological memory.
An evaluation of CLS’ products for treatment with Focal Laser Ablation (FLA) is initiated in the beginning of 2017. Image-guided FLA is a method primarily used today for treatment of early localized prostate cancer (PCA).